DCM
PTGX icon

DAFNA Capital Management’s Protagonist Therapeutics PTGX Stock Holding History

DAFNA Capital Management’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-45,586
Closed -$1M – 76
2016
Q4 		$1M Sell
45,586
-78,218
-63% -$1.74M 0.88% 37
2016
Q3 		$2.62M Buy
+123,804
New +$1.69M 1.82% 17

Other funds holding PTGX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
PI
Pharmstandard International Luxembourg $29M AUM 3.25% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
FCMI
Foresite Capital Management III Larkspur, California $37.9M AUM 6.87% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

DAFNA Capital Management's PTGX Position: Q1 2017 in Review

DAFNA Capital Management sold out of Protagonist Therapeutics (PTGX) in Q1 2017, closing a stake of 45,586 shares — an estimated $1M sold.

DAFNA Capital Management first reported a position in PTGX in Q3 2016 and held it in 2 quarters. The position peaked at $2.62M in Q3 2016. 40 funds tracked by Wall St. Rank hold PTGX as of Q1 2017.

  • DAFNA Capital Management reported no remaining Protagonist Therapeutics position as of Q1 2017 after selling out during the quarter.
  • DAFNA Capital Management sold 45,586 Protagonist Therapeutics shares in Q1 2017, an estimated $1M.
  • DAFNA Capital Management first reported a position in Protagonist Therapeutics in Q3 2016 and held it in 2 quarters.
  • DAFNA Capital Management's Protagonist Therapeutics position peaked at $2.62M in Q3 2016.
  • 40 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q1 2017.

Based on DAFNA Capital Management's 13F filing for Q1 2017, filed 15 May 2017.